AFP and hepatocellular carcinoma: With respect to the strong performance of DKK-1 as a response marker across patients with different AFP levels in our study, we feel that DKK-1 needs to be further investigated for its potential as a tool for navigating treatment decisions, ideally not only for TACE but also for other HCC treatments.